Daniel Wang counsels and supports our clients in the areas of public policy, regulatory strategy, abuse potential assessment, and risk management for opioids, cannabinoids and other CNS-active compounds. He also supports the development and coordination of postmarketing and risk management surveillance programs, including contributing to reports based on surveillance from Internet and media monitoring, public use datasets, and proprietary datasets. Additionally, Dan contributes to PinneyAssociates’ science, policy, and marketing intelligence efforts.
Before joining PinneyAssociates in 2010, Daniel coordinated early phase clinical trials in oncologic drug development at the Hospital of the University of Pennsylvania. Daniel graduated from the University of Pennsylvania in 2008 with a Bachelor of Arts Degree in the biological basis of behavior.